CG
SLDB icon

Cutler Group’s Solid Biosciences SLDB Stock Holding History

Cutler Group’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-633
Closed -$2K – 6003
2021
Q3 		$2K Buy
+633
New +$26.9K ﹤0.01% 5087
2019
Q4 		– Sell
-80
Closed -$3K – 4543
2019
Q3 		$3K Buy
+80
New +$9.05K ﹤0.01% 3350
2019
Q2 		– Sell
-120
Closed -$1K – 4746
2019
Q1 		$1K Buy
+120
New +$30.1K ﹤0.01% 3793

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cutler Group's SLDB Position: Q4 2022 in Review

Cutler Group sold out of Solid Biosciences (SLDB) in Q4 2022, closing a stake of 47 shares.

Cutler Group first reported a position in SLDB in Q4 2018 and held it in 15 quarters. The position peaked at $32K in Q1 2019. 35 funds tracked by Wall St. Rank hold SLDB as of Q4 2022.

  • Cutler Group reported no remaining Solid Biosciences position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 47 Solid Biosciences shares in Q4 2022.
  • Cutler Group first reported a position in Solid Biosciences in Q4 2018 and held it in 15 quarters.
  • Cutler Group's Solid Biosciences position peaked at $32K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.